Porton Pharma Solutions Ltd. Conquers Complex POC Project Through Collaborative Innovation

In today's fast-paced biomedical technology landscape, new drug R&D is transitioning from traditional small molecules to new molecular domains, marked by increasingly complex molecular structures. While interdisciplinary integration offers opportunities, it also escalates R&D challenges exponentially. The rise of conjugation technology and the lack of mature experience in new molecular research necessitate CDMOs to elevate their new molecular platform services and multidisciplinary collaboration capabilities. A prime example is the POC (Peptide-Oligonucleotide Conjugate) project, which involves cross-disciplinary technologies and demands precision in synthesis, purification, and analysis to avoid project failure.

Recently, Porton Pharma Solutions Ltd. earned high praise from a client for its exceptional performance in a complex POC project involving oligonucleotide and peptide, underscoring its prowess in tackling intricate projects. Entrusted by a Chinese innovative drug company, Porton faced multiple hurdles, including challenging process development, stringent impurity control, and rigorous quality standards. Porton swiftly assembled a cross- disciplinary team of experts in oligonucleotide R&D, peptide R&D, purification, analysis, and a dedicated project management to tackle these challenges collaboratively.

The oligonucleotide R&D team led the charge, breaking through technical bottlenecks to develop a stable synthesis, aminolysis, and conjugation process, which was successfully scaled up. Simultaneously, the peptide team leveraged its deep technical expertise to conquer key steps such as peptide synthesis, cleavage, and modification, delivering high-purity intermediates with improved yields and shortened delivery time.

In the purification phase, the team devised targeted methods to effectively remove impurities from complex mixtures of oligonucleotide, peptide, and conjugated product, achieving industry-leading purity levels. The analysis team optimized methods for this complex molecule, ensuring reliable quality control throughout the project. The project management team acted as a cohesive force, establishing efficient communication channels and coordinating resources in real time to ensure seamless collaboration across all stages. Thanks to meticulous planning and rigorous quality control at every step, from process development to production delivery, the project was completed ahead of schedule, with product purity and yield surpassing expectations.

In a letter of appreciation, this client stated, "Porton's professionalism and collaborative spirit throughout the project were truly impressive. Every aspect, from technology R&D to project execution, and from quality control to business communication, demonstrated a high level of expertise, proving Porton's comprehensive capability in handling complex projects."

This success underscores Porton's long-standing commitment to new drug R&D services, technological innovation, and team building. Looking ahead, as the pharmaceutical industry faces escalating technological demands and increasingly complex project challenges, Porton will remain customer-centric, enhancing its cross-disciplinary collaborative innovation capabilities. By injecting more professional strength into global pharmaceutical R&D, Porton aims to accelerate the transition of complex innovative drug projects from the lab to the clinic, ultimately benefiting patients and Enabling the public's early access to good medicines.

About Porton Tides CDMO Platform

Porton Tides CDMO Platform operates multiple R&D centers and GMP-compliant production facilities in Shanghai and Chongqing, China. This enables us to deliver end-to-end CDMO solutions, supporting global pharmaceutical companies and new drug developers from preclinical discovery through commercialization. Our core services include: Process Development & Optimization, Toxicology Batch Production, Clinical-Stage Sample Production, Structural Characterization, Analytical Method Development & Validation, In-Process Controls & Release Testing, ICH-Compliant Stability Studies, and CMC Services such as pharmaceutical documentation support for regulatory filings. By integrating these services into a cohesive CMC offering, we accelerate the development of innovative therapies, Enabling the public's early access to good medicines.

About Porton Biologics and Conjugates CDMO Platform